Saturday, September 23, 2023
Saturday, September 23, 2023

Intermountain Healthcare Selects Ikonopedia Breast Reporting and Risk Assessment Tools

Intermountain Healthcare, based in Salt Lake City, Utah, has selected Ikonopedia structured breast reporting and risk assessment tools to help improve reporting quality, efficiency, and maintain patient safety. The news was announced today.

The system-wide implementation will be initiated at six Intermountain Healthcare’s hospitals, including the Janice Beesley Hartvigsen Breast Care Center at Intermountain Medical Center, and features integration with the Cerner EHR and other imaging systems.

Intermountain Healthcare employs nearly 40,000 caregivers who serve the healthcare needs of people across the Intermountain West. Intermountain Healthcare performs more than 160,000 mammography exams a year, as well as provides comprehensive treatment for breast cancer and other breast-related conditions, at more than 25 locations in Utah, southern Idaho, and southern Nevada.

Intermountain Healthcare was named as one of “Health Care’s Most Wired” for 2016 by Hospitals & Health Networks magazine. The list is based on a collaborative study conducted by H&HN and the American Health Association. Intermountain has been named among the nation’s most technologically savvy hospital systems in 17 of the 18 years the survey has been conducted.

“While we expect Ikonopedia’s innovative Cloud-based structured breast reporting system to bring significant efficiency gains to our technologists and radiologists, the focus is on providing high-quality and safe care to every one of our patients,” said Brett Parkinson, MD, imaging director and medical director for breast care services at Intermountain. “This starts with utilizing intuitive, easy to use reporting and risk assessment tools and closed-loop follow-up system to make sure that every patient and every clinical finding is monitored and fully resolved.”

Ikonopedia is an innovative structured breast reporting and MQSA management system designed to dramatically improve reporting efficiency and optimize facility operations. All findings are saved as discrete data, which allows Ikonopedia to prevent errors, maintain BI-RADS-compliant language and automate many time-consuming processes. Ikonopedia makes it possible to eliminate laterality errors, automatically choose exam-appropriate patient letters, and pull forward findings from past exams along with many other time-saving features.

Ikonopedia’s integrated risk assessment tool is now available in dozens of languages and risk data is used to create alerts for the radiologist, populate the clinical section of the report, and automatically update the patient letter. A high-risk patient alert identifies patients with a 20% or greater lifetime risk and information about the score is instantly viewable.

“Intermountain Healthcare is well known for using technology to improve patient care, efficiency, and safety. We are proud to work with Intermountain to deliver robust breast reporting and risk-assessment tools that help ensure that women get accurate and timely information about their breast care, which can lead to better outcomes for their patients and caregivers,” said Emily Crane, CEO of Ikonopedia.

Medical Device News Magazinehttps://infomeddnews.com
Our publication is dedicated to bringing our readers the latest medical device news. We are proud to boast that our subscribers include medical specialists, device industry executives, investors, and other allied health professionals, as well as patients who are interested in researching various medical devices. We hope you find value in our easy-to-read publication and its overall purpose and objectives! Medical Device News Magazine is a division of PTM Healthcare Marketing, Inc. Pauline T. Mayer is the managing editor.

More News!

PADCEV® (enfortumab vedotin-ejfv) and KEYTRUDA® (pembrolizumab) Significantly Improve Overall Survival and Progression-Free Survival in Patients With Previously Untreated Advanced Bladder Cancer in Pivotal Phase...

The EV-302 study met its dual primary endpoints of overall survival (OS) and progression-free survival (PFS), compared to chemotherapy. An Independent Data Monitoring Committee determined that OS crossed the pre-specified efficacy boundary at interim analysis. The safety results of the combination are consistent with those of enfortumab vedotin in combination with pembrolizumab previously reported in cisplatin-ineligible patients with la/mUC.

NeuroBo Pharmaceuticals Doses First Patient in Its Phase 2a Clinical Trial Evaluating DA-1241 for the Treatment of NASH

"Dosing the first patient, on time, is a testament to our commitment to the clinical development of DA-1241 in patients with NASH," stated Hyung Heon Kim, President and Chief Executive Officer of NeuroBo. "Based on the pre-clinical and clinical evidence generated to date, DA-1241 has demonstrated reduced hepatic steatosis, hepatic inflammation, and liver fibrosis, while also improving glucose control, and was shown to be well tolerated in both healthy volunteers and in patients with type 2 diabetes mellitus (T2DM). Given this data, we believe that the mechanism of action of this promising cardiometabolic asset will translate into a safe and effective treatment for NASH, a disease with no current treatment options. The two-part design of this trial provides optionality for a potential interim analysis in the first half of 2024 and we expect to report the full data in the second half of 2024."

Medmain Inc. Has Been Selected for the U.S. Market Gateway Accelerator for BioSciences and MedTech

The "U.S. Market Gateway Accelerator for BioSciences and MedTech", sponsored by WorldUpstart, LLC, is an acceleration program that provides medical tech and life sciences startups with a proven track record outside the U.S. with the opportunity to enter and grow their business in the U.S. market.

Karger Publishers New Journal – Immune System

“Immune System is an innovative Open Access journal, welcoming articles with a broad background from basic science to clinical research, as long as the manuscript focuses on certain aspects of our immune response,” states editor-in-chief Désirée Larenas-Linnemann."

MindMed Completes Enrollment of Phase 2b Trial of MM-120 in Generalized Anxiety Disorder (GAD)

Robert Barrow, Chief Executive Officer and Director of MindMed. “Thanks in large part to the enthusiasm we have seen regarding MM-120 among investigators and patients, as well as the strong execution of our team, we were able to enroll almost 200 participants in this trial in just over a year. We anticipate sharing topline results during the fourth quarter of this year.”

By using this website you agree to accept Medical Device News Magazine Privacy Policy